Free Trial

Temple Bar (LON:TMPL) Sets New 52-Week High - Still a Buy?

Temple Bar logo with Financial Services background

Temple Bar (LON:TMPL - Get Free Report)'s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as GBX 322.80 ($4.41) and last traded at GBX 320 ($4.37), with a volume of 474747 shares trading hands. The stock had previously closed at GBX 320.50 ($4.38).

Temple Bar Stock Down 0.6%

The firm's 50 day simple moving average is GBX 310.82 and its 200 day simple moving average is GBX 292.84. The company has a market cap of £919.75 million, a price-to-earnings ratio of 5.97 and a beta of 1.11. The company has a quick ratio of 3.68, a current ratio of 5.17 and a debt-to-equity ratio of 9.47.

Temple Bar Company Profile

(Get Free Report)

Temple Bar's investment objective is to provide investors with a growing income combined with growth in capital. It aims to meet this objective by investing primarily in UK equities, across different sectors, maintaining a balance of larger and smaller/medium-sized companies. The trust has a bias towards FTSE 350 companies.

Recommended Stories

Should You Invest $1,000 in Temple Bar Right Now?

Before you consider Temple Bar, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Temple Bar wasn't on the list.

While Temple Bar currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines